Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction

Circulation

Volumn 105, Issue 7, 2002, Pages 868-873

  Hayashidani, Shunji ^a   Tsutsui, Hiroyuki ^a   Shiomi, Tetsuya ^a   Suematsu, Nobuhiro ^a   Kinugawa, Shintaro ^a   Ide, Tomomi ^a   Wen, Jing ^a   Takeshita, Akira ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Cholesterol; Heart failure; Metalloproteinases; Myocardial infarction; Remodeling

Indexed keywords

COLLAGENASE 3; FLUINDOSTATIN; GELATINASE A; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DRUG EFFECT; ENZYME ACTIVITY; FIBROSING ALVEOLITIS; HEART FAILURE; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; LONG TERM CARE; LUNG WEIGHT; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME;

ADMINISTRATION, ORAL; ANIMALS; BLOTTING, WESTERN; BODY WEIGHT; DILATATION, PATHOLOGIC; DISEASE MODELS, ANIMAL; ECHOCARDIOGRAPHY; FATTY ACIDS, MONOUNSATURATED; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; LUNG; MALE; MATRIX METALLOPROTEINASES; MICE; MYOCARDIAL INFARCTION; MYOCARDIUM; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; ORGAN SIZE; PEPTIDYL-DIPEPTIDASE A; SURVIVAL RATE; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 0037133338     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/hc0702.104164     Document Type: Article

References (25)

1. Ventricular remodeling after myocardial infarction: Experimental observations and clinical implications
2. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the Survival and Ventricular Enlargement Trial. The SAVE Investigators
3. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
4. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
5. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators
6. Molecular bases of the acute coronary syndromes
7. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts
8. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase
9. Treatment with dimethylthiourea prevents left ventricular remodeling and failure after experimental myocardial infarction in mice: Role of oxidative stress
10. Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers
11. Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: Relation to ventricular and myocyte function
12. Myocardial matrix degradation and metalloproteinase activation in the failing heart: A potential therapeutic target
13. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice
14. Fluvastatin inhibits matrix metalloproteinase-1 expression in human vascular endothelial cells
15. Simvastatin inhibits leukocyte-endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats
16. Selective activation of cardiac angiotensinogen gene expression in post- infarction ventricular remodeling in the rat
17. Inhibitory effects of fluvastatin, a new HMG-CoA reductase inhibitor, on the increase in vascular ACE activity in cholesterol-fed rabbits
18. Simvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosis
19. Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells
20. HMG-CoA reductase inhibitors attenuate angiotensin-II induced cardiac hypertrophy
21. Nitric oxide decreases cytokine-induced endothelial activation: Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines
22. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease
23. Matrix metalloproteinase inhibition after myocardial infarction: A new approach to prevent heart failure?
24. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction
25. Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor α can be modulated by anti- tumor necrosis factor a therapy